From Trial Populations To Pricing: How Some Of The COVID-19 Vaccines Compare
With Phase III underway, Pfizer and Moderna’s clinical approaches and government contracting strategies are coming into focus.
You may also be interested in...
While AstraZeneca’s adenovirus candidate is expected to use Operation Warp Speed’s platform, its start date remains cloaked; the Janssen and Novavax candidates are expected to enter Phase III in September and October, respectively.
US FDA’s ‘may be effective’ standard for granting an emergency use authorization is expected to be comparable to the substantial evidence of effectiveness needed to support full licensure of a COVID-19 vaccine, although EUA allows for a more rapid review, agency officials say.
National Academy of Medicines is developing a framework for equitable COVID-19 vaccine distribution which, CDC and NIH hope, will help shore up public trust ahead of the unenviable task of having to decide who should be the first to get limited vaccine resources. CDC Director Robert Redfield said the distribution strategy should help lessen the health disparities seen with COVID-19 infections.